Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world

PurposeThis study aimed to assess the efficacy and safety of a triple therapy that comprises transarterial chemoembolization (TACE), antiangiogenic-targeted therapy, and programmed death-1 (PD-1) inhibitors in a real-world cohort of patients with unresectable hepatocellular carcinoma (HCC) with port...

Full description

Bibliographic Details
Main Authors: Jin-Kai Feng, Zong-Han Liu, Zhi-Gang Fu, Zong-Tao Chai, Ju-Xian Sun, Kang Wang, Yu-Qiang Cheng, Hong-Fei Zhu, Yan-Jun Xiang, Li-Ping Zhou, Jie Shi, Wei-Xing Guo, Jian Zhai, Shu-Qun Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma (HCC)
portal vein tumor thrombus (PVTT)
transarterial chemoembolization (TACE)
anti-angiogenic targeted therapy
PD-1 inhibitor
immune checkpoint inhibitor (ICI)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.954203/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.954203/full

Similar Items